Dr. Martin has been a full professor at Stanford University for several years and is affiliated with several programs, including the Stanford Cancer Research Institute. He has contributed to many areas of biological research, e.g., bacterial infections and their treatment; discovery of new drugs and therapeutic enzymes and their improvement. He has pioneered mRNA-based gene delivery specifically to cancer using exosomes promising cure without side-effects – this approach is applicable to gene delivery-mediated treatment also of other diseases. He did his Ph. D. at UCLA, spent some years in the Netherlands (State University of Groningen), where he directed a research group, before joining Stanford. He is a recipient of numerous awards and honors.
Ken H. Young is a Professor at The University of Texas MD Anderson Cancer Center in the Department of Hematopathology. Young completed his MD at Zhejiang University School of Medicine, China in 1984. Dr. Ken primary study of genomic alterations is on TP53 tumor suppressor pathway. His secondary focus is on Myc oncogene. Weblink to MD Anderson SciVal research profile and PubMed list of publication is attached. Ken research team performs several types of hematologic malignancies, with special emphasis on pathogenesis of malignant lymphomas, especially diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive B-cell lymphoma which brings together the worst characteristics of both high-grade features and aggressive biology. The disease is incurable in nearly 40% patients. Ken has published over 134 articles in different journals. Dr. Ken has worked as committee member at American Board of Pathology, Anatomic and Clinical Pathology, and the American Board of Hematology. Currently, Dr. Ken is Vice-Chair for the IRG Pilot Grant Review Committee at The University of Texas MD Anderson Cancer Center, Houston.
Dr. Whiteside is a professor of Pathology, Immunology, and Otolaryngology and a member of the University of Pittsburgh Cancer Institute. Dr. Whiteside is a clinical immunologist with many years of experience in evaluating human immune-mediated diseases. Dr. Whiteside is served as Director of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) at the UPMC Hillman Cancer Center for 25 years and am currently serving as Interim Director. The IMCPL offers a broad spectrum of immunodiagnostic and monitoring assays for testing of patients with cancer. The laboratory also serves as a cGMP facility which generates cellular products for immunotherapy of patients with cancer and HIV.
DR. ALAIN L. FYMAT is a medical-physical scientist and an educator. He is the current President/ CEO and Institute Professor at the International Institute of Medicine & Science with a previous appointment as Executive Vice President/Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine, California, U.S.A. He was formerly Professor of Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine, and Physics at several U.S. and European Universities. Earlier, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs (Office of Research Oversight). At the Loma Linda Veterans Affairs Medical Center, he was Scientific Director of Radiology, Director of the Magnetic Resonance Imaging Center and, for a time, Acting Chair of Radiology. Previously, he was Director of the Division of Biomedical and Biobehavioral Research at the University of California at Los Angeles/Drew University of Medicine and Science. He was also Scientific Advisor to the U.S. National Academy of Sciences, National Research Council, for its postdoctoral programs tenable at the California Institute of Technology and Member of the Advisory Group for Research & Development, North Atlantic Treaty Organization (NATO). He is Health Advisor to the American Heart & Stroke Association, Coachella Valley Division, California. He is a frequent Keynote Speaker and Organizing Committee member at several international scientific/medical conferences. He has lectured extensively in the U.S.A, Canada, Europe, Asia, and Africa. He has publishedin excess of 475 scholarly scientific publications and books. He is also Editor-in-Chief, Honorable Editor or Editor of numerous medical/scientific Journals to which he regularly contributes. He is a member of the New York Academy of Sciences and the European Union Academy of Sciences, a Board member of several institutions, and a reviewer for the prestigious UNESCO Newton Prize, United Kingdom National Commission for UNESCO. Dr. Fymat's current research interests are focused on neurodegenerative diseases (Alzheimer's, Parkinson's, dementias, epilepsy, and others), oncology (glioblastoma), epigenetics & ecogenetics, and nanomedicine & nanobiotechnology. These are represented in part in his latest books: “From the Heart to the Brain: My collected works in medical science research (2016-2018)”, “Alzhei ...Who? Demystifying the disease and what you can do about it”, “The Odyssey of Humanity's Diseases: Epigenetic and ecogenetic modulations from ancestry through inheritance, environment, culture and behavior” Volumes 1, 2, and 3, “Parkin..ss..oo..nn: Elucidating the disease and what you can do about it”, “Lyme disease: The great invader, evader, and imitator”, and “Dementia: Fending-off the menacing disease... and what you can do about it”.
Dr. Jianwei Zhu spent his post-doctoral research at MIT and Harvard Medical School to develop his expertise for the career in biopharmaceutical development. Since 1997, Jianwei played technical leadership role in the Biopharmaceutical Development Program at Frederick National Laboratory for Cancer Research for developing ~38 biopharmaceuticals mainly for phase I to III clinical trials. His expertise in clinical development of biopharmaceuticals has been provided through consultation services to a number Institutes including International Vaccine Institute (United Nation found) and NIH as well as to biopharmaceutical companies internationally. He recently has been awarded as Distinguished Expert by the "Thousand Expert Plan" of China and pointed as “ZhiYuan” Chair Professor, and Director of the Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, at Shanghai JiaoTong University.